Projects In Knowledge: Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice

PLEASE NOTE:

As required by the ACCME, all participants must read the information below before proceeding to this activity.

After doing so, please click the View Webcast button at the bottom of this page.

In this free CME/CE on-demand webcast, a panel of experts in the use of targeted therapies to treat patients with NSCLC will provide up-to-date information on optimizing the use of targeted agents, discussing genomic predictors and their application in determining therapy with targeted agents, current and emerging targeted therapies, and multimodality radiotherapy/targeted therapy.

Chair
	Walter J. Curran, Jr., MD Lawrence W. Davis Professor and Chair Department of Radiation Oncology Emory University School of Medicine Atlanta, Georgia
Faculty
	George R. Blumenschein, Jr., MD Associate Professor Department of Thoracic Head & Neck Medical Oncology The University of Texas, M. D. Anderson Cancer Center Houston, Texas	Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology Department of Medical Oncology University of Colorado Denver Aurora, Colorado

AGENDA
Welcome and Introduction Walter J. Curran, Jr., MD
Genomic Profiling of NSCLC for EGFR Inhibitors Fred R. Hirsch, MD, PhD
Current and Emerging Targeted Therapies in NSCLC George R. Blumenschein, Jr., MD
Targeted Therapy and Multimodality Treatment in NSCLC Walter J. Curran, Jr., MD
Questions & Answers Faculty Panel

top

Target Audience
This activity is designed for physicians, including medical oncologists, radiation oncologists, pulmonologists, and other clinicians involved in the care of patients with non-small cell lung cancer.

Activity Goal
The goal of this activity is to provide the latest data and strategies for combining targeted therapies with cytotoxic chemotherapy and radiotherapy to optimize the treatment and outcomes of patients with non-small cell lung cancer.
top

Learning Objectives

•	Assess the genetic profiles of non-small cell lung tumors to determine potentially beneficial therapeutic interventions that improve patient outcomes.
•	Formulate treatment regimens for non-small cell lung cancer patients that combine chemotherapy, radiotherapy, and targeted therapies, utilizing an understanding of appropriate patient selection and stratification criteria, as well as efficacy and safety data.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge^® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.00 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists

Projects In Knowledge^® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This webcast is worth up to 1.00 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this application activity is 052-000-09-057-H01-P.
top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Walter J. Curran, Jr., MD, is a consultant for Amgen Inc, Eli Lilly and Company, Genentech, Inc, and ImClone Systems; and has received salary/honoraria from Bristol-Myers Squibb. Dr. Curran will be discussing off-label/investigational use of cetuximab and gefitinib.

George R. Blumenschein, Jr., MD, is a consultant for Abbott Laboratories, Amgen Inc, and Genentech, Inc. Dr. Blumenschein will be discussing off-label/investigational use of cetuximab, gefitinib, sorafenib, sunitinib, and vandetanib.

Fred R. Hirsch, MD, PhD, is a consultant for AstraZeneca, Bristol-Myers Squibb/ImClone Systems, Genentech/OSI, GlaxoSmithKline, Merck & Company, Novartis Pharmaceuticals, and Syndax Pharmaceuticals; and receives research support from Genentech, Inc., Merck & Company, OSI Pharmaceuticals, Syndax Pharmaceuticals, and Ventana-Roche. He is also co-inventor of a University of Colorado-owned patent licensed to Abbott Laboratories. Dr. Hirsch will be discussing off-label/investigational use of cetuximab, gefitinib, and erlotinib.

Karen Gravelle, PhD, has no significant relationships to disclose.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

	View Webcast Requires Flash 8 or higher and high-speed internet
top	1914.01